Home > Publications Database > Retrospective analysis of neurofilament-light chain in patients with inflammatory bowel disease – A pilot study > print

001     284356
005     20260212105836.0
024 7 _ |a 10.1371/journal.pone.0340182
|2 doi
037 _ _ |a DZNE-2026-00124
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wolff, Andreas
|0 P:(DE-2719)9003609
|b 0
|u dzne
245 _ _ |a Retrospective analysis of neurofilament-light chain in patients with inflammatory bowel disease – A pilot study
260 _ _ |a San Francisco, California, US
|c 2026
|b PLOS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770812631_18489
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Chronic inflammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, are characterized by persistent inflammation of the gastrointestinal tract. While traditionally regarded as confined to the gut, the systemic nature of inflammatory bowel disease has been increasingly recognized. The nervous system has garnered particular attention due to molecular and clinical evidence suggesting a potential interplay between inflammatory bowel disease and neurodegenerative diseases. Inflammatory bowel disease patients have a higher risk of developing neurological disorders such as Parkinson's disease, all-cause dementia, and multiple sclerosis. Still, causative molecular mechanisms are poorly understood. Neurofilament light chain (NfL) has been established as a disease-independent biomarker of axonal damage reflecting neurodegeneration.In this pilot study, we assessed molecular evidence of neurodegeneration by measuring serum NfL in a single-molecule array using the HD-X SIMOA platform (Quanterix, MA, USA) and employing correlation with clinical data in forty-nine patients with histopathologically confirmed inflammatory bowel disease. In total, 24 Crohn's disease patients, 25 ulcerative colitis patients, and 23 controls, aged 18-79 years, were included.We found an age-dependency of serological NfL levels, however, no apparent differences between disease groups and controls. Crohn's disease patients showed a slower age-dependent incline in serological NfL compared to control subjects (p = 0.03). No correlation of NfL with disease duration, disease severity, or inflammatory bowel disease treatment was found.A slower age-dependent increase in serological NfL levels was found in Crohn's disease patients compared to control subjects. Larger studies assessing additional markers of neurodegeneration may be instrumental in addressing this question in the future.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Pilot Projects
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Inflammatory Bowel Diseases: blood
|2 MeSH
650 _ 2 |a Crohn Disease: blood
|2 MeSH
650 _ 2 |a Crohn Disease: pathology
|2 MeSH
650 _ 2 |a Colitis, Ulcerative: blood
|2 MeSH
650 _ 2 |a Colitis, Ulcerative: pathology
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
700 1 _ |a Feneberg, Emily
|b 1
700 1 _ |a Shakhtour, Julius
|b 2
700 1 _ |a Steiger, Katja
|0 0000-0002-7269-5433
|b 3
700 1 _ |a Schmid, Roland M.
|b 4
700 1 _ |a Haller, Bernhard
|b 5
700 1 _ |a Reinhardt, Nya
|b 6
700 1 _ |a Middelhoff, Moritz
|b 7
700 1 _ |a Schult-Hannemann, David
|b 8
700 1 _ |a Lingor, Paul
|0 P:(DE-2719)2812561
|b 9
|e Last author
773 _ _ |a 10.1371/journal.pone.0340182
|g Vol. 21, no. 1, p. e0340182 -
|0 PERI:(DE-600)2267670-3
|n 1
|p e0340182
|t PLOS ONE
|v 21
|y 2026
|x 1932-6203
856 4 _ |u https://pub.dzne.de/record/284356/files/DZNE-2026-00124%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/284356/files/DZNE-2026-00124.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/284356/files/DZNE-2026-00124.pdf?subformat=pdfa
856 4 _ |u https://pub.dzne.de/record/284356/files/DZNE-2026-00124%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/284356/files/DZNE-2026-00124%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/284356/files/DZNE-2026-00124%20SUP.pdf
909 C O |o oai:pub.dzne.de:284356
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9003609
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812561
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PLOS ONE : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-08T09:37:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-08T09:37:46Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21